[go: up one dir, main page]

MX2017008655A - Derivados de jasmonato y composiciones de los mismos. - Google Patents

Derivados de jasmonato y composiciones de los mismos.

Info

Publication number
MX2017008655A
MX2017008655A MX2017008655A MX2017008655A MX2017008655A MX 2017008655 A MX2017008655 A MX 2017008655A MX 2017008655 A MX2017008655 A MX 2017008655A MX 2017008655 A MX2017008655 A MX 2017008655A MX 2017008655 A MX2017008655 A MX 2017008655A
Authority
MX
Mexico
Prior art keywords
compositions
jasmonate
conjugates
jasmonate derivatives
derivatives
Prior art date
Application number
MX2017008655A
Other languages
English (en)
Inventor
E Fehr Pereira Lopes José
Original Assignee
Nanocare Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocare Tech Inc filed Critical Nanocare Tech Inc
Publication of MX2017008655A publication Critical patent/MX2017008655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con conjugados de jasmonato y conjugados de jasmonato nanoportados y/o microportados y composiciones farmacéuticas de los mismos, así como con el uso de los mismos para el tratamiento o prevención de los trastornos relacionados con la angiogénesis o relacionados con NF-KB. También se describen métodos para la elaboración de los conjugados.
MX2017008655A 2014-12-31 2015-12-31 Derivados de jasmonato y composiciones de los mismos. MX2017008655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098704P 2014-12-31 2014-12-31
PCT/US2015/068244 WO2016109779A1 (en) 2014-12-31 2015-12-31 Jasmonate derivatives and compositions thereof

Publications (1)

Publication Number Publication Date
MX2017008655A true MX2017008655A (es) 2018-04-10

Family

ID=56285070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008655A MX2017008655A (es) 2014-12-31 2015-12-31 Derivados de jasmonato y composiciones de los mismos.

Country Status (11)

Country Link
US (2) US10314918B2 (es)
EP (1) EP3240534A4 (es)
JP (1) JP2018502855A (es)
KR (1) KR20170125811A (es)
AU (1) AU2015373915A1 (es)
BR (1) BR112017014229A2 (es)
CA (1) CA2971870A1 (es)
IL (1) IL253212A (es)
MX (1) MX2017008655A (es)
WO (1) WO2016109779A1 (es)
ZA (1) ZA201705100B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370253B (es) 2011-09-16 2019-12-06 Nanocare Tech Inc Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
GB202306865D0 (en) * 2023-05-10 2023-06-21 Univ Stellenbosch Conjugate and composition for treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE124422T1 (de) 1989-04-12 1995-07-15 Procter & Gamble Festes verbraucherprodukt, welches feinteilige cyclodextrin-komplexe enthält.
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP3568325B2 (ja) 1996-07-12 2004-09-22 株式会社ノエビア 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料
JP3596835B2 (ja) 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
JP2002504118A (ja) 1997-06-09 2002-02-05 ザ、プロクター、エンド、ギャンブル、カンパニー 体臭および過剰湿気を軽減する芳香組成物および方法
US6790815B1 (en) 1998-07-10 2004-09-14 Procter & Gamble Company Amine reaction compounds comprising one or more active ingredient
CA2274873A1 (en) * 1999-07-06 2001-01-06 Satinder Gidda Methods and compositions for modulating flowering
EP1372739A4 (en) 2001-03-08 2005-10-19 Targesome Inc STABILIZED THERAPEUTIC AND IMAGING AGENTS
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US20040209795A1 (en) 2003-04-21 2004-10-21 Vlad Florin Joseph VOC-free microemulsions
WO2005054172A2 (en) 2003-12-02 2005-06-16 Ramot At Tel-Aviv University Ltd. Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
KR100789343B1 (ko) 2004-09-07 2007-12-28 주식회사 엘지생활건강 화장용 분체, 그의 제조방법 및 이를 함유하는 메이컵화장품 조성물
EP1814894B1 (de) 2004-11-25 2012-08-08 Merck Patent GmbH Flavonoid-komplexe mit cyclodextrinen
US7258878B2 (en) 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
ES2265291B1 (es) 2005-07-22 2008-03-01 Universidad De Alcala Nuevos dendrimeros carbosilanos, su preparacion y sus usos.
WO2007066336A2 (en) * 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US8247439B2 (en) 2005-12-07 2012-08-21 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US20070207981A1 (en) 2006-03-06 2007-09-06 Eva Almenar Micro-encapsulation of volatile compounds into cyclodextrins: a new technology to reduce post harvest losses
EP2027136A4 (en) 2006-06-13 2011-08-03 Cargill Inc Large part cyclicxtrin inclusion complexes and method for their preparation
JP2009542799A (ja) * 2006-07-10 2009-12-03 ラモト アット テル − アビブ ユニバーシティー リミテッド 組合せ癌治療方法
BRPI0604024A (pt) 2006-09-01 2008-04-22 Beyond Lifescience Pesquisa De alimentos para a prevenção do cáncer e composições farmacêuticas à base do jasmonato
BRPI0720888A2 (pt) 2006-12-27 2014-03-25 Cargill Inc Complexos de inclusão de ciclodextrina e métodos de preparar os mesmos
WO2009019693A2 (en) 2007-08-07 2009-02-12 Sepal Pharma Sa Analgesic effect of jasmonate derivatives
CA2700426C (en) 2007-09-25 2017-10-31 Galia Temtsin Krayz Compositions comprising lipophilic active compounds and method for their preparation
GB0721761D0 (en) 2007-11-06 2007-12-19 Plant Bioscience Ltd Compositions and methods for synergistic manipulation of plant and insect defences
WO2009067404A2 (en) 2007-11-19 2009-05-28 New Biology, Inc. Methods for improving flowering characteristics using methyl dihydrojasmonate
US20090197939A1 (en) 2008-02-01 2009-08-06 Mary Kay Inc. Methods of treating skin with aromatic skin-active ingredients
ES2328002B2 (es) * 2008-02-29 2010-03-29 Universidad De Alicante Uso combinado de metil-jasmonato y ciclodextrinas para la produccion de resveratrol.
BRPI0804172A2 (pt) 2008-07-15 2010-07-06 Pereira Lopes Jose Emilio Fehr compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos
US20120083529A1 (en) 2009-06-09 2012-04-05 Sepal Pharma Ltd Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
CN101818100B (zh) 2010-04-15 2012-06-06 上海应用技术学院 聚氰基丙烯酸丁酯包覆大花茉莉香精胶囊的制备方法
CN105078973B (zh) * 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
AU2012221877A1 (en) 2011-02-25 2013-09-19 Nanocare Technologies, Inc. Pharmaceutical formulation comprising compounds of the jasmonate family
MX370253B (es) 2011-09-16 2019-12-06 Nanocare Tech Inc Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
EP2583998B1 (en) 2011-10-21 2018-02-28 Borealis AG Polyethylene composition with high rapid crack propagation resistance and pressure resistance
US9187402B2 (en) * 2012-06-14 2015-11-17 North Carolina Agricultural And Technical State University Aspirin derivatives and uses thereof
BR112015000236A2 (pt) 2012-07-10 2017-06-27 Baseclick Gmbh moléculas de ácidos nucleicos modificadas por anandamida

Also Published As

Publication number Publication date
US10314918B2 (en) 2019-06-11
US20200164074A1 (en) 2020-05-28
IL253212A (en) 2018-04-30
ZA201705100B (en) 2021-01-27
EP3240534A4 (en) 2018-12-19
JP2018502855A (ja) 2018-02-01
BR112017014229A2 (pt) 2018-03-06
EP3240534A1 (en) 2017-11-08
KR20170125811A (ko) 2017-11-15
CA2971870A1 (en) 2016-07-07
WO2016109779A1 (en) 2016-07-07
US20170368186A1 (en) 2017-12-28
AU2015373915A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MY192927A (en) Fused bicyclic compounds for the treatment of disease
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
GB2541571A (en) Pharmaceutical compositions
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
EP3310358A4 (en) COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2016015298A (es) Inhibidores de nampt y metodos.